



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,590	01/27/2004	Boris Tabakoff	UTC-08617	3842
7590	01/19/2006		EXAMINER	
Christine A. Lekutis MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, CA 94105			SITTON, JEHANNE SOUAYA	
		ART UNIT	PAPER NUMBER	
		1634		

DATE MAILED: 01/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/766,590	TABAKOFF ET AL.	
	Examiner	Art Unit	
	Jehanne S. Sitton	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 27 January 2004.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-28 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-28 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - 1-11. Claims 1-7, drawn to a method of identifying individuals predisposed to alcohol tolerance and dependence by screening for a biomarker using nucleic acid based methods, classified in class 435, subclass 6. Each group is directed to a patentably distinct biomarker set forth in claims 1-3.
 - 12-22. Claims 1-4, drawn to a method of identifying individuals predisposed to alcohol tolerance and dependence by screening for a biomarker using, classified in class 435, subclass 7.1. Each group is directed to a patentably distinct biomarker set forth in claims 1-3.
 23. Claims 8-10, 12, and 13, drawn to a method of identifying an individual at reduced risk of developing alcohol dependence by screening for at least one biomarker of the 16p13.3 locus, and more specifically, the AC9 gene, classified in class 435, subclass 6.
 24. Claims 8-9, 11-18, drawn to a method of identifying individuals at reduced risk of developing alcohol dependence or increased risk for alcohol abuse by screening for at least one biomarker of the 16q12.2 locus, and more specifically repeats in the AC7 gene, classified in class 435, subclass 6.
 25. Claims 19-23, drawn to a kit comprising a reagent capable of specifically detecting at least one polymorphism in an all of the AC9 gene, or a gene in linkage disequilibrium, classified in class 536, subclass 23.1.

26. Claims 19-23 drawn to a kit comprising a reagent capable of specifically detecting at least one polymorphism in an all of the AC7 gene, or a gene in linkage disequilibrium, classified in class 536, subclass 23.1.

27-38. Claims 24-28, drawn to a method of screening compounds by using at least one allele of a gene selected from 12 different genes, classified in class 514, subclass 1. Each group is directed to a patentably distinct biomarker set forth in claim 24.

2. It is noted that although claims 1-3 will be limited to restriction to a patentably distinct biomarker (any of claims 1-3 not directed to a specific biomarker will be withdrawn from consideration as being drawn to a non elected invention), once a biomarker is elected, claims 1, and 2 or 3, as presently written, will not be limited to protein or nucleic analysis. This subject is considered to link the inventions in claims 4-7. Therefore, once a biomarker is elected, should claims 1 and, 2 or 3, be found allowable with regard to any screening analysis for the specific biomarker, the restriction requirement between claims 4-7 (nucleic acid vs protein analysis) shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) directed to a specific biomarker, will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C.

121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

3. The inventions are distinct, each from the other because of the following reasons:

Groups 1-11, 23, and 24 are patentably distinct from each other. Groups 12-22, 23, and 24 are patentably distinct from each other. Groups 27-38 are patentably distinct from each other. Groups 25 and 26 are patentably distinct from each other. The groups are directed to methods of analyzing structurally and functionally distinct biomarkers encoding different proteins. They are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 USC 121 and 37 CFR 1.141. By statute, “[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions.” 35 U.S.C. 121. Pursuant to this statute, the rules provide that “[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant... to elect that invention to which his claim shall be restricted.” 37 CFR 1.142 (a). See also 37 CFR 1.141(a). It is noted that searching more than one of the claimed patentably distinct biomarkers represents a serious burden for the office.

The methods of Groups 1-11 are patentably distinct from the methods of groups 12-22 because they are drawn to methods requiring different modes of operation, different reaction parameters, and different methods of analysis. They are unobvious over one another because

expression changes or levels of mRNA are not necessarily predictive of protein expression and vice versa. Additionally, a search burden exists for searching each of the patentably distinct group as the search for nucleic acid expression of a specific gene will not necessarily provide any information regarding protein expression, and vice versa. Accordingly the searches are not coextensive. Therefore, the methods of groups 1-11 and 12-22 are patentably distinct.

The inventions of groups 1-24 are unrelated to the inventions of groups 27-38. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different functions, and different effects.

The inventions of groups 23 & 24 and the inventions of groups 25 & 26, respectively, are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the kits of groups 25 and 26 include restriction enzymes which can be used for other methods of analysis than those for groups 23 and 24. Alternatively, the kits can comprise probes which can be used to make proteins which are not required to practice the methods of groups 23 or 24. Search for each group is not coextensive as art related to restriction enzymes or nucleic acids will not necessarily provide any information regarding the detection of the specifically claimed alleles for methods of determining alcohol abuse risk.

The inventions of groups 25 and 26 are unrelated to the inventions of groups 27-38.

Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different functions, and different effects. Further, the kits of groups 25 and 26 are not used in the methods of groups 27-38.

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

5. Because these inventions are distinct for the reasons given above and the search required for each group is different restriction for examination purposes as indicated is proper.

6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

9. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.**

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined.

See “Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-0752. The examiner can normally be reached Monday-Thursday from 8:00 AM to 5:00 PM and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571) 272-0745. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Jehanne Sitton

Jehanne Sitton
Primary Examiner
Art Unit 1634

1/17/06